PRTA
Prothena Corporation plc
Price Chart
Latest Quote
$8.93
+0.44 (+5.18%)
Current Price
| Previous Close | $8.49 |
| Open | $8.63 |
| Day High | $9.15 |
| Day Low | $8.52 |
| Volume | 1,390,843 |
Stock Information
| Shares Outstanding | 52.35M |
| Total Debt | $7.65M |
| Cash Equivalents | $329.46M |
| Revenue | $57.94M |
| Net Income | $-151.18M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $467.51M |
| EPS (TTM) | $-2.81 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $145.71M |
| Sales | $57.94M |
| Income | $-151.18M |
| Book/sh | $5.89 |
| Cash/sh | $6.29 |
| Employees | 67 |
Financial Ratios
| Quick Ratio | 10.13 |
| Current Ratio | 10.43 |
| Debt/Eq | 2.45 |
Returns & Margins
| ROA | -13.78% |
| ROE | -40.30% |
| Gross Margin | -66.84% |
| Operating Margin | 50.49% |
| Profit Margin | -260.92% |
Ownership
| Insider Ownership | 20.76% |
| Institutional Ownership | 90.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.82 |
| P/S | 8.07 |
| P/B | 1.52 |
Analyst Data
| Recommendation | none |
| Target Price | $21.40 |
Technical Indicators
| SMA20 | $9.03 |
| SMA50 | $9.88 |
| SMA200 | $9.64 |
| RSI | 35.01 |
| ATR | 0.5633 |
| Shares Float | 36.50M |
| Short Float | 17.73% |
| Short Ratio | 14.27 |
| Volatility | -0.32 |
| Rel Volume | 2.48 |
Performance History
| Week | +8.11% |
| Month | -1.54% |
| Quarter | +4.57% |
| 6 Months | -8.41% |
| YTD | -2.93% |
| Year | +56.67% |
| 3 Years | -88.32% |
| 5 Years | -80.20% |
| 10 Years | -78.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $8.93 | 1,390,800 |
| 2026-06-17 | $8.49 | 543,000 |
| 2026-06-16 | $8.29 | 586,300 |
| 2026-06-15 | $8.15 | 622,600 |
| 2026-06-12 | $8.25 | 315,400 |
| 2026-06-11 | $8.26 | 634,200 |
| 2026-06-10 | $7.91 | 457,000 |
| 2026-06-09 | $8.47 | 493,500 |
| 2026-06-08 | $8.56 | 313,200 |
| 2026-06-05 | $8.79 | 656,300 |
| 2026-06-04 | $9.25 | 504,900 |
| 2026-06-03 | $8.92 | 593,200 |
| 2026-06-02 | $9.19 | 439,000 |
| 2026-06-01 | $9.59 | 457,800 |
| 2026-05-29 | $10.18 | 501,400 |
| 2026-05-28 | $9.98 | 281,800 |
| 2026-05-27 | $10.03 | 616,200 |
| 2026-05-26 | $10.06 | 918,600 |
| 2026-05-22 | $9.83 | 510,900 |
| 2026-05-21 | $9.41 | 388,700 |
| 2026-05-20 | $9.35 | 624,900 |
| 2026-05-19 | $9.07 | 627,300 |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual AÃ-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-AÃ antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
đ° Latest News
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Zacks âĸ 2026-06-12T09:44:00Z
High Insider Ownership Growth Stocks To Watch In May 2026
Simply Wall St. âĸ 2026-05-28T17:35:41Z
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St. âĸ 2026-05-11T13:17:08Z
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
Motley Fool âĸ 2026-04-29T22:07:49Z
3 Growth Companies Insiders Are Eager To Hold
Simply Wall St. âĸ 2026-04-29T11:36:19Z
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
Zacks âĸ 2026-04-01T15:04:00Z
Top Growth Companies With High Insider Ownership In March 2026
Simply Wall St. âĸ 2026-03-31T17:36:08Z
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
Zacks âĸ 2026-03-31T16:12:00Z
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Zacks âĸ 2026-03-30T16:16:00Z
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Zacks âĸ 2026-03-27T15:30:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $9,684,000 | $135,157,000 | $91,370,000 | $53,905,000 |
| Operating Revenue | $9,684,000 | $135,157,000 | $91,370,000 | $53,905,000 |
| Expenses | ||||
| Total Expenses | $194,244,000 | $289,718,000 | $282,406,000 | $185,462,000 |
| Other Income Expense | $-30,408,000 | $-185,000 | $-458,000 | $-397,000 |
| Net Non Operating Interest Income Expense | $14,139,000 | $25,816,000 | $31,014,000 | $6,349,000 |
| Operating Expense | $194,244,000 | $289,718,000 | $282,406,000 | $185,462,000 |
| General And Administrative Expense | $59,392,000 | $67,199,000 | $61,835,000 | $49,900,000 |
| Other Non Operating Income Expenses | - | - | $-458,000 | $-397,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Net Interest Income | $14,139,000 | $25,816,000 | $31,014,000 | $6,349,000 |
| Interest Income | $14,139,000 | $25,816,000 | $31,014,000 | $6,349,000 |
| Normalized Income | $-217,485,000 | $-122,134,499 | $-146,608,391 | $-116,579,359 |
| Net Income From Continuing And Discontinued Operation | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Total Operating Income As Reported | $-214,640,000 | $-154,561,000 | $-191,036,000 | $-131,557,000 |
| Net Income Common Stockholders | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Net Income | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Net Income Including Noncontrolling Interests | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Net Income Continuous Operations | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Pretax Income | $-200,829,000 | $-128,930,000 | $-160,480,000 | $-125,605,000 |
| Special Income Charges | $-30,080,000 | $0 | $0 | - |
| Interest Income Non Operating | $14,139,000 | $25,816,000 | $31,014,000 | $6,349,000 |
| Operating Income | $-184,560,000 | $-154,561,000 | $-191,036,000 | $-131,557,000 |
| Per Share | ||||
| Diluted EPS | $-4.53 | $-2.27 | $-2.76 | $-2.47 |
| Basic EPS | $-4.53 | $-2.27 | $-2.76 | $-2.47 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,801,000 | $-9,499 | $-38,391 | $-27,359 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-153,257,000 | $-153,483,000 | $-189,650,000 | $-130,416,000 |
| Total Unusual Items | $-30,408,000 | $-185,000 | $-458,000 | $-397,000 |
| Total Unusual Items Excluding Goodwill | $-30,408,000 | $-185,000 | $-458,000 | $-397,000 |
| Reconciled Depreciation | $895,000 | $893,000 | $928,000 | $744,000 |
| EBITDA (Bullshit earnings) | $-183,665,000 | $-153,668,000 | $-190,108,000 | $-130,813,000 |
| EBIT | $-184,560,000 | $-154,561,000 | $-191,036,000 | $-131,557,000 |
| Diluted Average Shares | $53,829,000 | $53,772,000 | $53,216,000 | $47,369,000 |
| Basic Average Shares | $53,829,000 | $53,772,000 | $53,216,000 | $47,369,000 |
| Diluted NI Availto Com Stockholders | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Tax Provision | $43,263,000 | $-6,620,000 | $-13,452,000 | $-8,656,000 |
| Restructuring And Mergern Acquisition | $30,080,000 | $0 | $0 | - |
| Gain On Sale Of Security | $-328,000 | $-185,000 | $-458,000 | $-397,000 |
| Research And Development | $134,852,000 | $222,519,000 | $220,571,000 | $135,562,000 |
| Selling General And Administration | $59,392,000 | $67,199,000 | $61,835,000 | $49,900,000 |
| Other Gand A | $59,392,000 | $67,199,000 | $61,835,000 | $49,900,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Total Assets | $326,804,000 | $547,108,000 | $696,382,000 | $758,035,000 |
| Total Non Current Assets | $11,611,000 | $61,696,000 | $57,100,000 | $38,937,000 |
| Other Non Current Assets | $1,342,000 | $4,668,000 | $7,209,000 | $12,725,000 |
| Non Current Deferred Assets | $0 | $43,239,000 | $33,893,000 | $18,204,000 |
| Non Current Deferred Taxes Assets | $0 | $43,239,000 | $33,893,000 | $18,204,000 |
| Current Assets | $315,193,000 | $485,412,000 | $639,282,000 | $719,098,000 |
| Other Current Assets | $1,753,000 | $1,165,000 | $2,140,000 | $1,708,000 |
| Prepaid Assets | $5,909,000 | $12,859,000 | $11,801,000 | $6,922,000 |
| Cash Cash Equivalents And Short Term Investments | $307,531,000 | $471,388,000 | $618,830,000 | $710,406,000 |
| Cash And Cash Equivalents | $307,531,000 | $471,388,000 | $618,830,000 | $710,406,000 |
| Restricted Cash | - | $0 | $1,352,000 | $0 |
| Receivables | - | $0 | $5,159,000 | $62,000 |
| Accounts Receivable | - | $0 | $5,159,000 | $0 |
| Other Receivables | - | - | - | $62,000 |
| Debt | ||||
| Total Debt | $8,373,000 | $10,843,000 | $11,835,000 | $6,473,000 |
| Long Term Debt And Capital Lease Obligation | $5,487,000 | $8,233,000 | $10,721,000 | $0 |
| Current Debt And Capital Lease Obligation | $2,886,000 | $2,610,000 | $1,114,000 | $6,473,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $46,330,000 | $60,182,000 | $135,017,000 | $135,993,000 |
| Total Non Current Liabilities Net Minority Interest | $5,487,000 | $11,681,000 | $78,126,000 | $85,846,000 |
| Non Current Deferred Liabilities | $0 | $3,448,000 | $67,405,000 | $85,293,000 |
| Current Liabilities | $40,843,000 | $48,501,000 | $56,891,000 | $50,147,000 |
| Other Current Liabilities | $13,739,000 | $1,375,000 | $2,417,000 | $503,000 |
| Current Deferred Liabilities | $2,664,000 | $8,850,000 | $0 | $11,442,000 |
| Payables And Accrued Expenses | $21,554,000 | $35,666,000 | $53,360,000 | $31,729,000 |
| Payables | $5,875,000 | $7,770,000 | $25,391,000 | $9,270,000 |
| Accounts Payable | $5,875,000 | $7,770,000 | $25,391,000 | $9,270,000 |
| Other Non Current Liabilities | - | - | - | $553,000 |
| Total Tax Payable | - | - | - | - |
| Income Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Total Equity Gross Minority Interest | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Stockholders Equity | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Retained Earnings | $-1,346,433,000 | $-1,102,341,000 | $-980,031,000 | $-833,003,000 |
| Other | ||||
| Ordinary Shares Number | $53,832,982 | $53,826,982 | $53,682,117 | $52,103,608 |
| Share Issued | $53,832,982 | $53,826,982 | $53,682,117 | $52,103,608 |
| Tangible Book Value | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Invested Capital | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Working Capital | $274,350,000 | $436,911,000 | $582,391,000 | $668,951,000 |
| Capital Lease Obligations | $8,373,000 | $10,843,000 | $11,835,000 | $6,473,000 |
| Total Capitalization | $280,474,000 | $486,926,000 | $561,365,000 | $622,042,000 |
| Additional Paid In Capital | $1,626,369,000 | $1,588,729,000 | $1,540,859,000 | $1,454,524,000 |
| Capital Stock | $538,000 | $538,000 | $537,000 | $521,000 |
| Common Stock | $538,000 | $538,000 | $537,000 | $521,000 |
| Non Current Deferred Revenue | $0 | $3,448,000 | $67,405,000 | $85,293,000 |
| Long Term Capital Lease Obligation | $5,487,000 | $8,233,000 | $10,721,000 | $0 |
| Current Deferred Revenue | $2,664,000 | $8,850,000 | $0 | $11,442,000 |
| Current Capital Lease Obligation | $2,886,000 | $2,610,000 | $1,114,000 | $6,473,000 |
| Current Accrued Expenses | $15,679,000 | $27,896,000 | $27,969,000 | $22,459,000 |
| Net PPE | $10,269,000 | $13,789,000 | $15,998,000 | $8,008,000 |
| Accumulated Depreciation | $-7,052,000 | $-8,308,000 | $-7,415,000 | $-11,168,000 |
| Gross PPE | $17,321,000 | $22,097,000 | $23,413,000 | $19,176,000 |
| Other Properties | $8,125,000 | $10,708,000 | $12,162,000 | $6,277,000 |
| Machinery Furniture Equipment | $9,196,000 | $11,389,000 | $11,251,000 | $11,401,000 |
| Treasury Shares Number | - | - | $0 | - |
| Leases | - | - | $0 | $1,498,000 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-163,718,000 | $-150,348,000 | $-136,716,000 | $-109,285,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-163,580,000 | $-150,050,000 | $-133,906,000 | $-108,821,000 |
| Cash Flow From Continuing Operating Activities | $-163,580,000 | $-150,050,000 | $-133,906,000 | $-108,821,000 |
| Operating Gains Losses | $104,000 | - | $15,000 | $1,000 |
| Investing Activities | ||||
| Capital Expenditure | $-138,000 | $-298,000 | $-2,810,000 | $-464,000 |
| Investing Cash Flow | $-138,000 | $-298,000 | $-2,773,000 | $-464,000 |
| Cash Flow From Continuing Investing Activities | $-138,000 | $-298,000 | $-2,773,000 | $-464,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-139,000 | $-353,000 | - | - |
| Issuance Of Capital Stock | $0 | $0 | $23,583,000 | $223,616,000 |
| Financing Cash Flow | $-139,000 | $1,554,000 | $45,103,000 | $241,457,000 |
| Cash Flow From Continuing Financing Activities | $-139,000 | $1,554,000 | $45,103,000 | $241,457,000 |
| Net Common Stock Issuance | $-139,000 | $-353,000 | $23,583,000 | $223,616,000 |
| Common Stock Issuance | $0 | $0 | $23,583,000 | $223,616,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $931,000 | $3,172,000 | $1,554,000 | $2,659,000 |
| End Cash Position | $308,391,000 | $472,248,000 | $621,042,000 | $712,618,000 |
| Beginning Cash Position | $472,248,000 | $621,042,000 | $712,618,000 | $580,446,000 |
| Changes In Cash | $-163,857,000 | $-148,794,000 | $-91,576,000 | $132,172,000 |
| Proceeds From Stock Option Exercised | $0 | $1,907,000 | $21,520,000 | $17,841,000 |
| Common Stock Payments | $-139,000 | $-353,000 | - | - |
| Net PPE Purchase And Sale | $-138,000 | $-298,000 | $-2,773,000 | $-464,000 |
| Sale Of PPE | $0 | $0 | $37,000 | $0 |
| Purchase Of PPE | $-138,000 | $-298,000 | $-2,810,000 | $-464,000 |
| Change In Working Capital | $-4,173,000 | $-67,943,000 | $-20,530,000 | $-18,803,000 |
| Change In Other Working Capital | $-9,634,000 | $-55,107,000 | $-29,330,000 | $-13,855,000 |
| Change In Other Current Liabilities | $10,609,000 | $-2,236,000 | $-6,359,000 | $-6,004,000 |
| Change In Payables And Accrued Expense | $-15,776,000 | $-18,298,000 | $22,855,000 | $11,865,000 |
| Change In Payable | $-15,776,000 | $-18,298,000 | $22,855,000 | $11,865,000 |
| Change In Account Payable | $-15,776,000 | $-18,298,000 | $22,855,000 | $11,865,000 |
| Change In Prepaid Assets | $10,628,000 | $2,539,000 | $-2,537,000 | $-10,809,000 |
| Change In Receivables | $0 | $5,159,000 | $-5,159,000 | $0 |
| Changes In Account Receivables | $0 | $5,159,000 | $-5,159,000 | $0 |
| Other Non Cash Items | $2,807,000 | $2,692,000 | $7,484,000 | $5,997,000 |
| Stock Based Compensation | $37,640,000 | $45,964,000 | $40,914,000 | $31,322,000 |
| Deferred Tax | $43,239,000 | $-9,346,000 | $-15,689,000 | $-11,133,000 |
| Deferred Income Tax | $43,239,000 | $-9,346,000 | $-15,689,000 | $-11,133,000 |
| Depreciation Amortization Depletion | $895,000 | $893,000 | $928,000 | $744,000 |
| Depreciation And Amortization | $895,000 | $893,000 | $928,000 | $744,000 |
| Gain Loss On Sale Of PPE | $104,000 | $0 | $15,000 | $1,000 |
| Net Income From Continuing Operations | $-244,092,000 | $-122,310,000 | $-147,028,000 | $-116,949,000 |
| Depreciation | - | - | - | - |
Fetched: 2026-06-21